close

Welcure Drugs & Pharmaceuticals Ltd

Know More
NSEBSE
Stock not tradded

3.82-0.03 (-0.78%)

04:01 PM,29th Sep 2023

BSE : 524661

NSE :

Sector : Health care

ISIN Code : INE331C01017

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Sep 29 2023 | 04:01 PM IST

Market Cap (₹ Cr)

0

Turnover (₹ Cr)

0.00

Volume (Shares)

Face Value

10

52-WK High

0.00

52-WK High Date

Invalid date

52-WK Low

0.00

52-WK Low Date

Invalid date

All Time High

0.00

All Time High Date

Invalid date

All Time Low

0.00

All Time Low Date

Invalid date

Welcure Drugs & Pharmaceuticals Ltd

Incorporated on 4 Jun.'92 Welcure Drugs And Pharmaceuticals (WDPL) was promoted by D C Jain Sanjeev Jain and Sandeep Jain. The promoters have interests in other companies such as Paam Pharmaceuticals Pioneer Products Alirox Abrasives A K Laboratories etc. The company is managed by managing director D C Jain.WDPL had come out with a Rs 4-cr public issue in Aug.'94 to part-finance the Rs 7-cr project to manufacture bulk drugs in Rajasthan and finance investments in a subsidiary A K Laboratories (AKL). The company has also submitted the letter of offer for a Rs 7.09-cr rights issue of equity shares in Jan.'96 to finance its expansion programmes.Products of WDPL include bulk drugs such as ampicillin and trimethoprim drugs intermediates and pharmaceutical formulations. It has decided to add amoxycillin and cloxacillin to its range with provision to manufacture ibuprofen. It manufactures over a hundred varieties of tablets capsules and dry syrups sulpha drugs vitamins analgesics etc. Its subsidiary AKL manufactures 6-APA a key drug intermediate in the manufacture of semi-synthetic penicillin. The company has decided to set up new sections of paediatrics and veterinary drugs and to diversify into ointments and liquid syrups. The new products of the company WELSTAP X- CLOX ETHAMBUTOL RIFA- Z CETIRIZIN NORTIN have been well accepted in the market.The Company has entered into a collaboration agreement with a russian company to act as their sole selling agent for a unique medicine Stevioside an alternate to sugar Saccharin and Aspartame.The Company has added a new liquid oral plant in Bhiwadi Rajasthan. It has obtained ISO 9002 certification with double accredition from ABS Quality Evaluation Inc Texas and by Registrar of Accredition Board of USA. Welcure has also entered into an agreement with Bihar Drugs and Chemicals Ltd a government of Bihar undertaking for manufacturing their products in its factory on loan basis.During the year 2000-01 the company had launched some products like CEZENDIMCIN PLUSOXINSPASWIN etc.The company has entered into technical collaboration agreement with Advanced Medical Care Inc New Jersey USA for setting up of joint venture facilities in the existing plant of the company.During the year 2001-02 the company had launched products like B-ZEX DMART PLUS DRALPIN DUKESPAS DUBAMOL HISTACURE KUFFWEL KINGSPAS LANAX PETRIMAX PEEROSCAM RENACT SARVO WELCEE WELGESIC WELIC WELOXY WELRELEEF X-DRYL.The company has changed its marketing policy from Sales through Wholesale Distributors to Sales at Doorstep by reaching every corner of the country and by putting dual force on Sales-through sales personnel on one hand and through stockists and distributors on the other hand.

Welcure Drugs & Pharmaceuticals Ltd - Key Fundamentals

PARAMETER VALUES
Market Cap (₹ Cr)

5

EPS - TTM (₹) [S]

0.00

P/E Ratio (X) [S]

3.26

Face Value (₹) 10
Latest Dividend (%)-
Latest Dividend Date -
Dividend Yield (%) -
Book Value Share (₹) [S]1.17
P/B Ratio (₹) [S]3.26
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High

3.20

3.89

Week Low/High

3.20

4.00

Month Low/High

3.20

4.00

Year Low/High

3.20

10.00

All time Low/High

0.36

40.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week-1.80%%-0.27-0.18%
1 Month-0.78%%1.161.53%
3 Month-6.60%%2.993.51%
6 Month-3.29%%14.2615.85%
1 Year-55.32%%16.7016.77%
3 Year%%73.3574.99%

Financials

Graph
Table

Bulk/ Block

ALL
NSE
BSE
ALL
BUY
SELL
DateClient NameExchangeTransactionQuantityPrice
14-12-2022SYEDUMARBSESELL735005.66
06-12-2022N L RUNGTA HUFBSESELL1285005.28
06-12-2022N L RUNGTA HUFBSEBUY300005.30
06-12-2022PARESH DHIRAJLAL SHAHBSEBUY677765.30
06-12-2022PARESH DHIRAJLAL SHAHBSESELL500025.30
02-12-2022DEEPA NAVIN PAMNANIBSESELL1107214.39
02-12-2022DINESH KUMAR JAINBSESELL1800004.81
02-12-2022MADHUDEVI SANJAY BUCHABSESELL1000014.47
02-12-2022N L RUNGTA HUFBSEBUY1045004.47
02-12-2022N L RUNGTA HUFBSESELL400004.80

Load More

Peer Group Comparison

NamePrice(In Rs)Chg(%)Mkt Cap(Rs Cr)Sales(Rs Cr)Profit(Rs Cr)EPS(Rs)P/E(x)

Shareholding Pattern

Jun 2023
Archive
CategoryShare(%)
Promoter0.00
Financial Institutions Banks0.00
Foreign Institutional Investors0.00
Insurance Companies0.00
Mutual Funds Uti0.00
Other Institutional Investors0.00
Indian Public93.67
Others Non Institutional Investors6.33
Custodians0.00

Corporate Action

Announcement DatePurposeFromToRemarks
Data Not Found

Price History

Search for Price History

DateOpenHighLowCloseSharesTrades
Data Not Found

Load more

Company Info

Company Information

Non-Exec. & Independent Dir. : Gagan Juneja

Independent Director : Mohd. Shahbaz Alam

Additional Director : Sitaben S Patel

Additional Director : Rajeev Mehra

Registered Office: B-9 & 10 Laxmi Towers, L S C Block-C Saraswati Vihar,Delhi,New Delhi-110034 Ph: 91-011-2701 1428

Email:investor.welcure@gmail.com

URL: